Meeting
2019 ASCO Annual Meeting
SHERLOC: A phase 2 study of MM-121 plus with docetaxel versus docetaxel alone in patients with heregulin (HRG) positive advanced non-small cell lung cancer (NSCLC).
Authors
Lecia V. Sequist
Massachusetts General Hospital Cancer Center/Harvard Medical School, Boston, MA
Lecia V. Sequist , Pasi A. Janne , Rudolf M. Huber , Jhanelle Elaine Gray , Enriqueta Felip , Maurice Perol , Fred R. Hirsch , Daniel Shao-Weng Tan , Geoffrey Kuesters , Alena Zalutskaya , Sergio Santillana , J. Marc Pipas , Frances A. Shepherd
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02387216
Citation
J Clin Oncol 37, 2019 (suppl; abstr 9036)
DOI
10.1200/JCO.2019.37.15_suppl.9036
Abstract #
9036
Poster Bd #
359
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
A phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG+), locally advanced or metastatic non-small cell lung cancer (NSCLC).
First Author: Lecia V. Sequist
Poster
2023 ASCO Quality Care Symposium
Real-world treatment patterns and clinical outcomes post standard of care (SOC) among patients (pts) with metastatic non-small cell lung cancer (mNSCLC) with and without actionable genomic alterations (AGAs) in the United States (US).
First Author: Ruchit Shah
Poster
2022 ASCO Annual Meeting
Quality of life (QoL) of OSE2101 in patients with HLA-A2+ non–small cell lung cancer (NSCLC) after failure to immune checkpoint inhibitors (IO): Final data of phase 3 Atalante-1 randomized trial.
First Author: Benjamin Besse
Poster
2018 ASCO Annual Meeting
Phase II open-label, multi-centre study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced NSCLC.
First Author: James Lorens